ASCL.F 주식 개요 생명공학 회사인 아스클레티스 파마는 중국 본토에서 의약품의 연구 개발, 제조, 마케팅 및 판매에 종사하는 기업입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Ascletis Pharma 과거 주가 현재 주가 HK$0.24 52주 최고치 HK$0.27 52주 최저치 HK$0.14 베타 0.58 1개월 변경 36.51% 3개월 변경 사항 n/a 1년 변경 사항 42.27% 3년 변화 4,686.00% 5년 변화 -63.18% IPO 이후 변화 -60.12%
최근 뉴스 및 업데이트
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Nov 13
Update on Legal Proceedings Involving Ascletis Pharma Inc.'s ASC41 and ASC43F Oct 07
Ascletis Pharma Inc. Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity Sep 17
Ascletis Pharma Inc. to Report Q2, 2024 Results on Aug 30, 2024 Jul 30
Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024 Jun 13
Ascletis Pharma Inc., Annual General Meeting, May 23, 2024 Apr 28 더 많은 업데이트 보기
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Nov 13
Update on Legal Proceedings Involving Ascletis Pharma Inc.'s ASC41 and ASC43F Oct 07
Ascletis Pharma Inc. Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity Sep 17
Ascletis Pharma Inc. to Report Q2, 2024 Results on Aug 30, 2024 Jul 30
Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024 Jun 13
Ascletis Pharma Inc., Annual General Meeting, May 23, 2024 Apr 28
Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 Apr 03
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting Mar 11
Ascletis Pharma Inc. to Report Fiscal Year 2023 Results on Mar 25, 2024 Feb 24
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne Jan 24
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis Jan 02
Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne Dec 05
Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure Sep 29
Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma Sep 27
Ascletis Pharma Inc. to Report Q2, 2023 Results on Aug 21, 2023 Jul 24
Ascletis Pharma Inc. Announces Completion of Patient Enrollment for Phase Ii Clinical Trial of Asc42, an Fxr Agonist, for Primary Biliary Cholangitis Jul 22
Ascletis Pharma Inc., Annual General Meeting, Jun 29, 2023 Jun 06
Ascletis Pharma Inc. Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection May 09
Ascletis Pharma Inc. Announces Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B Feb 17
Ascletis Pharma Announces U.S. FDA Approval of Conducting Phase IIA Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection Feb 01
Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China Nmpa Jan 27
Ascletis Pharma Inc. Doses 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19 Jan 17
Viking Therapeutics, Inc. Files Complaints Against Ascletis Pharma Inc Jan 03
Ascletis Announces Positive Phase I Clinical Results of Oral Rdrp Inhibitor Asc10 for Covid-19 Dec 13
Ascletis Pharma Inc. Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA Dec 08
Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor Asc40 for Acne Dec 02
Ascletis Pharma Inc. Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA Nov 30
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for Covid-19 by U.S. FDA Nov 24
Ascletis Pharma Inc. Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA Nov 18
Ascletis Pharma Inc. Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA Nov 16
Ascletis Pharma Inc. Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022 Nov 07
Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Nov 03
Ascletis Pharma Inc. Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication Oct 27
Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19 Oct 11
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase Ii Clinical Trial of Thrß Agonist Asc41 for 52-Week Treatment of Liver Biopsy-Proven Nash Oct 06
Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure Sep 28
Ascletis Pharma Inc. Announces Clinical Study of PD-L1 antibody ASC22 Sep 16
Ascletis Pharma Inc. Announces Change of Company Secretary Aug 23
Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA Aug 22
Vascletis Pharma Inc. Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis Aug 17
Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors Aug 08
Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA Aug 05
Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients Aug 04
Ascletis Pharma Inc. to Report First Half, 2022 Results on Aug 22, 2022 Jul 28
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19 Jul 07
Ascletis Pharma Inc. Announces Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection Jul 05
Ascletis Pharma Inc. Announces First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection Jun 29
Ascletis Pharma Inc. Announces the Latest Phase Iib Clinical Trial Results of Subcutaneous Pd-L1 Antibody Asc22 (Envafolimab) in Patients with Chronic Hepatitis B (Chb) At an Oral Parallel Session of the International Liver Congress™ 2022 Jun 28
Ascletis Pharma Inc. Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022 Jun 16
Ascletis Pharma Inc. Appoints John P. Gargiulo as Chief Business Officer Jun 13
Ascletis Pharma Inc., Annual General Meeting, Jun 16, 2022 May 25 Ascletis Pharma Inc. Announces Approval of Investigational New Drug Application
Ascletis Pharma Inc. Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19 Apr 20
Ascletis Pharma Inc. Receives Approval for Investigational New Drug Application by China National Medical Products Administration Apr 07
Ascletis Pharma Inc. Completes Patient Enrollment in Phase II Clinical Trial of ASC42 for Chronic Hepatitis B Indication Mar 31
Ascletis Pharma Inc. Announces the Latest Results of Preclinical Studies of Two Novel Anti-Cancer Drug Candidates,ASC61 and ASC60, to Be Presented At AACR Annual Meeting 2022 Mar 28
Ascletis Pharma Inc. to Report Fiscal Year 2021 Results on Mar 21, 2022 Mar 04
Ascletis Pharma Inc. Provides Earnings Guidance for the Year Ended December 31, 2021 Mar 01
Ascletis Pharma Inc. Provides Earnings Guidance for the Year Ended December 31, 2021 Feb 28
Ascletis Pharma Inc Announces Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients Feb 15
Ascletis Pharma Inc. Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant Feb 08
Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors Feb 07
Ascletis Pharma Inc. Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA Jan 27
Ascletis Pharma Inc. Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma Jan 24
Ascletis Pharma Inc. Announces U.S. Ind Approval of Asc22, A Subcutaneously Administered Pd-L1 Antibody for Functional Cure of Chronic Hepatitis B Jan 18
Ascletis Pharma Inc. Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne Jan 14
Ascletis Pharma Inc. Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication Jan 11
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors Jan 10
Gannex Announces Completion of the U.S. Phase I Trial of ASC43F Jan 04
Ascletis Pharma Inc. Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-COV-2 Virus Jan 03
Ascletis Pharma Inc. Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-Oral Direct Anti-Hcv Therapy Dec 03
Ascletis Pharma Inc Announces Positive Topline Results from the U.S. Phase I Trial of Drug-Drug Interactions in Healthy Subjects and Pharmacokinetics in Patients with NAFLD for Its THRß Agonist ASC41 Sep 08
Ascletis Pharma Inc. Announces Completion of the Bridging Study and Initiation of Phase II Trial of FXR Agonist Asc42 in China for Chronic Hepatitis B Indication Aug 25
Ascletis Pharma Inc.'s artner Sagimet Dosed First Patient in FASCINATE-2 Phase IIb Trial in NASH Patients with Moderate to Advanced Fibrosis Aug 17
Ascletis Pharma Inc. Announces China NMPA Approves Phase II Clinical Trial of Asc40 for the Treatment of Patients with Acne Aug 09
China NMPA Approves Ascletis Pharma Inc.'s Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma Jul 23
Ascletis Announces Dosing of the First Cohort of Healthy Subjects in the FXR Agonist ASC42 Bridging Study for Chronic Hepatitis B Indication in China Jul 14
Ascletis Pharma Inc. Receives China IND Approval of its FXR Agonist ASC42 for Chronic Hepatitis B Indication Jun 08
Gannex, a Wholly Owned Company of Ascletis Pharma Inc. Receives China IND Approval of Its FXR Agonist ASC42 for NASH Indication May 27
Ascletis Pharma Announces Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA May 25
Ascletis Pharma Inc. Announces Positive Phase IIa HBV Results on Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) May 05
Ascletis Pharma Inc. to Report Fiscal Year 2020 Results on Mar 29, 2021 Mar 18
Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-ß Agonist ASC41 for NASH Feb 26
Gannex Announces Positive Phase I Clinical Results on Its THR-ß Agonist ASC41 Jan 12
Ascletis Pharma Inc. Announces First Subject Dose with Gannex Pharma Co., Ltd.'s FXR Agonist Asc42 in U.S. Phase I Trial Dec 29
Ascletis Pharma Inc. Announces Subcutaneously PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study Dec 04
Ascletis Pharma Inc. Announces ASC40 (TVB-2640) Phase II Nash Trial Completed Patient Enrollment in China Nov 20
Ascletis Pharma Inc. Announces Approval for Its Nash Drug Candidate ASC42 Oct 13
Ascletis Pharma Inc. to Report First Half, 2020 Results on Aug 28, 2020 Aug 11 주주 수익률 ASCL.F US Biotechs US 마켓 7D 0% 0.7% 0.6% 1Y 42.3% -3.4% 23.7%
전체 주주 수익률 보기
수익률 대 산업: ASCL.F 지난 1년 동안 -3.4 %를 반환한 US Biotechs 산업을 초과했습니다.
수익률 대 시장: ASCL.F 지난 1년 동안 23.7 %를 반환한 US 시장을 초과했습니다.
가격 변동성 Is ASCL.F's price volatile compared to industry and market? ASCL.F volatility ASCL.F Average Weekly Movement n/a Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.5% 10% least volatile stocks in US Market 3.1%
안정적인 주가: ASCL.F 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: 지난 1년간 ASCL.F 의 변동성 변화를 확인하기에는 데이터가 충분하지 않습니다 .
회사 소개 생명공학 회사인 아스클레티스 파마는 중국 본토에서 의약품의 연구 개발, 제조, 마케팅 및 판매에 종사하고 있습니다. 이 회사는 리토나비르 정제, C형 간염 바이러스 치료제인 애클레비어와 가노보를 제공합니다. 또한 만성 B형 간염 및 HIV 기능 치료제인 ASC22, 호흡기 세포융합 바이러스 치료제인 ASC10, COVID-19 치료제인 ASC10 및 ASC11, 비알코올성 지방간염 치료제인 ASC40, ASC41, ASC42, ASC43F FDC, 원발성 담즙성 담관염 치료제인 ASC42를 개발 중입니다.
자세히 보기 Ascletis Pharma Inc. 기본 사항 요약 Ascletis Pharma 의 수익과 매출은 시가총액과 어떻게 비교하나요? ASCL.F 기본 통계 시가총액 US$365.36m 수익(TTM ) -US$35.42m 수익(TTM ) US$1.38m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) ASCL.F 손익 계산서(TTM ) 수익 CN¥10.09m 수익 비용 CN¥22.72m 총 이익 -CN¥12.63m 기타 비용 CN¥245.84m 수익 -CN¥258.47m
주당 순이익(EPS) -0.27 총 마진 -125.17% 순이익 마진 -2,561.68% 부채/자본 비율 0%
ASCL.F 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/29 20:19 장 마감 주가 2024/12/16 00:00 수익 2024/06/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Ascletis Pharma Inc. 7 애널리스트 중 2 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Ling Zhang China Merchants Securities (HK) Co., Ltd Mingrui Wang Everbright Securities Co. Ltd. Siao Ye Everbright Securities Co. Ltd.
4 더 많은 분석가 보기 
